MD Revolution Acquires NavCare to Expand Remote Patient Care Management Services

MD Revolution, a leading provider of remote care management and clinical services has acquired NavCare, a remote patient care services company specializing in comprehensive chronic care management (CCM).

The acquisition provides NavCare clients with enhanced clinical and patient management tools, patient engagement applications and bi-directional integrations. Direct patient care will continue to be delivered by the same teams as NavCare patients migrate to MD Revolution’s RevUp Care Management Platform. The expanded leadership team will support all clients.

MD Revolution has been at the forefront of remote health innovation since 2011, providing remote patient monitoring (RPM) and CCM to over 1,700 providers and 150,000 patients, collecting and evaluating over 19 million vital measurements through care delivery.

NavCare has been providing proactive and preventative health assessments, screenings, and vital tracking through connected remote monitoring devices, 24/7 Care Team support, and the NavCare Connect integrated health platform since 2008. NavCare is located in Augusta, Georgia.

“MD Revolution offers not only extensive experience but also the best technology platform, and proven SaaS offering, to serve our growing client base” said Rick Griffin, CEO, NavCare. “We share the same culture and desire to provide exceptional personalized care to our patients, along with maintaining the highest clinical standards.”

NavCare teams will become employees of MD Revolution. Chris MacInnis will become Chief Operating Officer of MD Revolution and Theresa Lantz will become Vice President of Client Success. They will Join Kyle Williams, CEO, Paul Huffman, VP of Sales and Marketing and Michael Moore, VP of Product Management to lead the combined teams.

“NavCare’s experience in hospitals and its track record with annual wellness visits (AWV) and transitional care management (TCM) aligns with our growth strategy,” said Kyle Williams, CEO, MD Revolution. “Our operations will allow for better scaling of services and our combined care delivery and account management teams will mean improved capabilities benefitting all of our clients.”

Williams said that this merger will lead to MD Revolution being able to offer greatly expanded service to clients and patients.

“With this new relationship, we look forward to continued growth as we expand our services to the marketplace,” Williams said.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.